Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature
Abstract
Purpose:
We comprehensively reviewed current efforts and advances in the field of chemotherapeutic and biologically targeted treatment options after the failure of cisplatin based, first line regimens for urothelial carcinoma.
Materials and Methods:
We searched MEDLINE®, Central®, and meeting abstracts of ASCO (American Society of Clinical Oncology) and ESMO (European Society for Medical Oncology) to identify original articles, reviews and retrospective analyses on second line treatment of urothelial carcinoma. Articles were included in analysis if they described prospective phase II/III studies or larger high quality retrospective studies of second line treatment of urothelial carcinoma.
Results:
Although considered a chemosensitive disease, most patients with advanced or metastatic urothelial carcinoma relapse after cisplatin based first line treatment. Today none of the commonly used drugs, ie paclitaxel, carboplatin and/or gemcitabine, are approved by the FDA (Food and Drug Administration) for second line systemic treatment. In Europe vinflunine plus best supportive care is the only option approved by the EMA (European Medicines Agency) with moderate clinical efficacy. Responses to combined chemotherapy approaches are often better but associated with remarkable toxicity. In patients who respond well to first line treatment and, thus, are considered cisplatin sensitive readministration of a platinum based combination regimen may be an option. To date targeted therapies do not have a role in second line treatment of urothelial cancer. Immunotherapeutic strategies to target the PD-1/PD-L1 axis are emerging. In a recent phase I trial evaluating the PD-L1 targeted monoclonal antibody MPDL3280A a promising 43% response rate with good tolerability was achieved, which led to an immediate breakthrough therapy designation by the FDA. Combining chemotherapy with targeted agents, eg weekly paclitaxel and pazopanib, also shows promising activity in this prognostically poor treatment situation.
Conclusions:
Response rates and survival are poor after second line chemotherapy for advanced or metastatic urothelial carcinoma. To improve outcomes of salvage treatment novel biologically targeted drugs as monotherapy or as part of a combination with conventional cytostatics are urgently needed.
References
- 1 : Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. Ann Oncol2011; 22: 245. Google Scholar
- 2 : Second-line chemotherapy for advanced urothelial cancer: because we should or because we can?. J Clin Oncol2009; 27: 4444. Google Scholar
- 3 : Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol2009; 27: 4454. Google Scholar
- 4 : Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol1997; 15: 1853. Google Scholar
- 5 : A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma. J Clin Oncol2013; 31. abstract e15613. Google Scholar
- 6 : Clinical benefit of second-line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study. J Clin Oncol2004; 22. abstract 4619. Google Scholar
- 7 : Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer1997; 75: 606. Google Scholar
- 8 : Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol2002; 20: 937. Google Scholar
- 9 : Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol2013; 14: 769. Google Scholar
- 10 : Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs2012; 30: 1984. Google Scholar
- 11 : A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy. J Clin Oncol2014; 32. abstract e15519. Google Scholar
- 12 : A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional call carcinoma. J Clin Oncol2015; 33. abstract 372. Google Scholar
- 13 : Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: a Japanese experience. Jpn J Clin Oncol2007; 37: 201. Google Scholar
- 14 : Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma—prognostic factors for response and improvement of quality of life. Onkologie2002; 25: 47. Google Scholar
- 15 : Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter1999; 150: 11. Google Scholar
- 16 : Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol2006; 24: 3451. Google Scholar
- 17 : Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs2007; 25: 265. Google Scholar
- 18 : The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. Oncologist2015; 20: 508. Google Scholar
- 19 : A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer2006; 94: 1395. Google Scholar
- 20 : Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer2009; 115: 4110. Google Scholar
- 21 : Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol2013; 24: 1466. Google Scholar
- 22 : Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Jpn J Clin Oncol2006; 36: 104. Google Scholar
- 23 : Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int J Urol2007; 14: 1000. Google Scholar
- 24 : Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract2006; 60: 27. Google Scholar
- 25 : Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol2009; 39: 244. Google Scholar
- 26 : Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol2008; 13: 510. Google Scholar
- 27 : Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol2011; 22: 288. Google Scholar
- 28 : Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study. Cancer1997; 80: 465. Google Scholar
- 29 : Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol2007; 52: 1115. Google Scholar
- 30 : Second-line therapy in bladder cancer. Curr Opin Urol2009; 19: 533. Google Scholar
- 31 : Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer2008; 98: 86. Google Scholar
- 32 : Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer2012; 48: 1141. Google Scholar
- 33 : Modified MVAC as a second-line treatment for patients with metastatic urothelial carcinoma after failure of gemcitabine and cisplatin treatment. Cancer Res Treat2014; 46: 172. Google Scholar
- 34 : Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer. Ann Oncol1993; 4: 793. Google Scholar
- 35 : Comprehensive molecular characterization of urothelial bladder carcinoma. Nature2014; 507: 315. Google Scholar
- 36 : Genome sequencing identifies a basis for everolimus sensitivity. Science2012; 338: 221. Google Scholar
- 37 : MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature2014; 515: 558. Google Scholar
- 38 : A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer. Ann Oncol2014; 25. abstract LBA23. Google Scholar
- 39 : Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol2012; 13: 810. Google Scholar
- 40 : A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer2013; 11: 477. Google Scholar
- 41 : Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer. J Clin Oncol2015; 33. abstract 294. Google Scholar
- 42 : Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma. J Clin Oncol2015; 33. abstract 295. Google Scholar
- 43 : Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol2012; 30: 507. Google Scholar
- 44 Sequist LV, Cassier P, Varga A et al: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected solid tumors. Presented at annual meeting of American Association for Cancer Research, San Diego, California, April 5-9, 2014, abstract CT326. Google Scholar
- 45 : Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol2013; 31. abstract 255. Google Scholar
- 46 : Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol2012; 30: 3545. Google Scholar
- 47 : A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer2009; 115: 2881. Google Scholar
- 48 : Management of advanced bladder cancer in the era of targeted therapies. Minerva Urol Nefrol2015; 67: 103. Google Scholar
- 49 : Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer2014; 12: 130. Google Scholar
